Align Technology (ALGN) 2025 Earnings Quality Report

Grade: C — Receivables Rising While Growth Stalls

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-27, fiscal year ended December 31, 2025) + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP — Clean opinion (1 Critical Audit Matter)

One-line verdict: Align's Invisalign franchise is stuck. Revenue grew just 0.9% to $4.035B in 2025, Clear Aligner revenue barely moved (+0.5% to $3.245B), and CFFO fell 19.6% from $738M to $593M. The most concerning signal is that accounts receivable grew 10.7% to $1.10B — for a company whose revenue barely grew. DSO jumped from 91 days to 100 days, a 9-day increase, and has risen 13 days since 2023. In parallel, PricewaterhouseCoopers' Critical Audit Matter identifies an unusually complex revenue-recognition estimate: Align's Clear Aligner contracts contain "multiple future performance obligations" whose standalone selling prices depend on "usage rates" — essentially, an estimate of how many additional aligners each customer will order over the treatment life. That estimate drives the allocation of revenue between periods. Taken together, the slowing growth, rising receivables, and judgment-heavy revenue recognition warrant careful footnote reading. The balance sheet itself is pristine — $1.1B of cash against only $114M of debt, Z-Score 4.60.

Business: Two Segments, Invisalign Dominates

Per Item 1 of the 10-K: "We have two operating segments: (1) Clear Aligner and (2) Imaging Systems and CAD/CAM Services ('Systems and Services'). For the year ended December 31, 2025, Clear Aligner net revenues represented approximately 80% of worldwide net revenues, while Systems and Services net revenues represented the remaining 20%."

The MD&A provides the full breakdown:

Within Clear Aligner, the 10-K describes the product mix: "Comprehensive Products include, but are not limited to, Invisalign Comprehensive, Invisalign First and Invisalign Comprehensive 3in3. Non-Comprehensive Products include, but are not limited to, Invisalign Moderate, Lite and Express packages, Invisalign Go and Invisalign Go Plus and Invisalign Palatal Expander."

Systems and Services comprises "iTero intraoral scanning systems, which includes a single hardware platform and restorative or orthodontic software options, scanner wand upgrades" and the recently-acquired "exocad's CAD/CAM software solutions."

The two-year trend is clear: Clear Aligner revenue has grown from $3.20B to $3.25B (+1.4% total over two years). In a market where the company has been the dominant player for two decades, the Invisalign franchise has hit a wall.

Profitability: Margin Contraction

Per the consolidated statements of operations:

Gross margin contracted 280 basis points from 70.0% to 67.2%. This passes the B4 check threshold (which catches margin moves >3pp), but is a meaningful deterioration. On flat revenue, a gross margin of 67.2% produces gross profit of $2,711M — $88M less than 2024, the majority of the net income decline.

R&D and SG&A have been flat-to-down in absolute dollars — management has clearly tightened expense discipline — but not enough to offset the gross margin pressure.

Cash Flow: Still Covers Net Income, But Trending Down

Per the consolidated statements of cash flows:

CFFO fell $145M (-19.6%) in 2025. That is the largest single-year decline in recent memory. The C1 check still passes because CFFO/NI remains above 1.0 (at 1.45), but the direction of travel is concerning. Free cash flow of $491M is down from $623M a year ago.

Where did the cash go? Per the balance sheet, accounts receivable grew $106M and other working capital adjustments consumed the rest.

The Receivables Red Flag

Per the balance sheet:

This is the screen's primary flag. A2 fails: AR outpaced revenue for two consecutive years. More concerning is the DSO trajectory — from 84 days to 100 days over three years, a 16-day increase. For reference, LLY's DSO climbed 10 days over the same period during 45% annual growth; Align's climbed 16 days on 0.9% growth.

Three possible explanations:

CFFO growth of -19.6% on revenue growth of +0.9% is also directionally weak, though the A3 check passes because the engine's threshold requires a larger divergence.

The Critical Audit Matter: Revenue Recognition and Usage Rates

PwC has audited Align since 1997 (28 years). The 2025 audit identifies one Critical Audit Matter: Revenue Recognition — Determination of Standalone Selling Price of Distinct Performance Obligations in Clear Aligner Contracts.

Per the audit report: "the Company recognized net revenues of $3.2 billion from its Clear Aligner segment for the year ended December 31, 2025. The Company enters into contracts ('treatment plans') that involve multiple future performance obligations... Management allocates revenues for each treatment plan based on each unit's standalone selling price."

The judgmental element: "Management also considers usage rates, which is the number of times a customer is expected to order additional aligners. Management's process for estimating usage rates requires significant judgment and evaluation of inputs, including historical usage data by region, country and channel."

PwC explains why this is a CAM: "The principal considerations for our determination that performing procedures relating to revenue recognition and the determination of standalone selling price of distinct performance obligations in Clear Aligner contracts is a critical audit matter are the significant judgment by management in determining the estimate of standalone selling price, which includes significant assumptions related to usage rates for each distinct performance obligation. This in turn led to significant auditor judgment, subjectivity, and effort in performing procedures to evaluate management's determination of the estimates of standalone selling price and usage rates."

This is important context for the A2 receivables flag. Align's Invisalign contracts are not simple product sales — they are treatment plans bundled with additional aligners, retention products, and refinements that may be ordered over multiple years. The "usage rate" estimate determines how much revenue is recognized upfront versus deferred. A change in estimated usage rates would directly affect both current period revenue and the accounts receivable balance, which includes billings for not-yet-delivered future aligners.

Balance Sheet: Pristine

This is one of the cleanest balance sheets in the healthcare sector. Cash of $1.1B exceeds total debt of $114M by nearly 10x. Debt/EBITDA is 0.1x. There is no leverage risk. Goodwill + intangibles of $586M equals just 14% of equity. The C4 and D1 checks both pass by wide margins.

The 18-Point Screening

Beneish M-Score components: DSRI 1.097 (elevated, matches A2), GMI 1.042 (margin deteriorated), AQI 1.014, SGI 1.009 (minimal growth), DEPI 0.590 (depreciation accelerated), SGAI 0.987, TATA -0.0293, LVGI 0.939.

The DEPI of 0.590 is unusually low — it suggests depreciation grew relative to PP&E, or that the company adjusted useful lives. Worth a footnote check but not mechanically concerning because the overall M-Score still passes.

The F-Score fraud probability of 0.27% is one of the lowest in the group. The Altman Z-Score of 4.60 is very strong.

Key Risks from the 10-K (Item 1A)

1. Single-Product Concentration

Clear Aligner (Invisalign) is approximately 80% of revenue. The 10-K warns throughout Item 1A that competition from "do-it-yourself" aligner companies, generic aligners, traditional metal braces, and other dental device manufacturers could erode market share.

2. Growth Stagnation

The flat 2025 revenue ($4.03B vs $4.00B) is the most important piece of context. Align was a 10-15% annual grower for most of its public history. Revenue per Clear Aligner case has come under pressure as the company pushed lower-priced "Moderate," "Lite," and "Express" packages to reach new customer segments.

3. Dental Practice Demand Cycles

Dental discretionary spending is highly sensitive to macroeconomic conditions. Orthodontic treatment is often deferred in downturns. The 10-K discloses these risks within Item 1A.

4. Revenue Recognition Judgment

The CAM itself is the most specific risk disclosure. The usage-rate assumption underlying Clear Aligner revenue recognition is management-judgmental. A hindsight revision to usage rates would affect multiple periods.

5. International Exposure

The 10-K describes manufacturing in Juarez, Mexico; the EMEA regional headquarters in Rotkreuz, Switzerland; and the APAC regional headquarters in Singapore. International operations carry currency risk, tariff risk, and longer collection cycles (consistent with the DSO trend).

Key Financial Trends (4-Year)

Summary

Grade: C. One red flag on a well-capitalized but slowing company.

Align Technology has an extraordinarily clean balance sheet — $1.1B cash against $114M debt, Z-Score 4.60, F-Score fraud probability 0.27% — and a 28-year audit relationship with PricewaterhouseCoopers that has produced a clean opinion. The M-Score of -2.52 is below the manipulation threshold.

But the 18-check screen flags one issue that matters:

A2 — Receivables growing 10.7% against revenue growth of 0.9%. DSO has climbed from 84 days in 2022 to 100 days in 2025 — a 16-day increase. The trajectory is monotonic (85 → 91 → 100 days). CFFO fell 19.6% in 2025 while revenue grew 0.9% — a directional warning even though the A3 check passes because CFFO/NI remains above 1.0. Gross margin contracted 280 basis points to 67.2%.

The context that makes this worth careful reading: PricewaterhouseCoopers' Critical Audit Matter flags Align's Clear Aligner revenue recognition as judgment-heavy, specifically the "usage rate" estimate that determines how much of a multi-aligner treatment contract is recognized upfront. A change in usage-rate estimates would flow through to both revenue and receivables. The CAM is PwC's formal disclosure that this estimate requires "significant auditor judgment, subjectivity, and effort."

The business itself is not in crisis — Align has no debt concerns, generates positive free cash flow, and the Systems and Services segment (iTero scanners, exocad CAD/CAM) is growing modestly. But the combination of stagnating growth, rising receivables, margin contraction, and judgmental revenue recognition is the textbook pattern that forensic screens are designed to surface.

Read the 10-K. Read Notes 1 and 16 on revenue recognition. Read the DSO footnote. Then decide whether Invisalign's growth story is just on pause or structurally broken.

**Disclaimer**: This report is based on Align Technology's fiscal year 2025 10-K filed with the SEC on February 27, 2026. This is NOT investment advice.

**About EarningsGrade**: We screen earnings reports for financial red flags using an 18-point forensic framework. Grade C means a limited number of specific items warrant investigation.